Affiliation: University of Minnesota
- Are there circumstances in which phase 2 study results should be practice-changing?Marcie R Tomblyn
Dept of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware St, SE, MMC 480, Minneapolis MN 55455, USA
Hematology Am Soc Hematol Educ Program . 2007..Specific examples and application of these concepts are discussed in this review...
- Donor lymphocyte infusions: the long and winding road: how should it be traveled?M Tomblyn
Adult Blood and Marrow Transplant Program, Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
Bone Marrow Transplant 42:569-79. 2008....
- Difficult stem cell mobilization despite adequate CD34+ cell dose predicts shortened progression free and overall survival after autologous HSCT for lymphomaM Tomblyn
Blood and Marrow Transplant Program, University of Minnesota, 420 Delaware Street SE, Minneapolis, MN 55455, USA
Bone Marrow Transplant 40:111-8. 2007..The poor clinical outcome of patients with difficult mobilization using either method identifies them as a high-risk group who might benefit from alternative therapies...
- Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantationMarcie Tomblyn
Blood and Marrow Transplant Program, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
Biol Blood Marrow Transplant 14:538-45. 2008..Modifications to refine patient assignment to the preferred conditioning intensity and reduce relapse risks with NMA approaches are needed...
- Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphomaV Bachanova
Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA
Bone Marrow Transplant 43:237-44. 2009....
- Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donorNavneet S Majhail
Blood and Marrow Transplant Program, Divisions of Medical and Pediatric Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota 55455, USA
Biol Blood Marrow Transplant 14:282-9. 2008..A careful review of existing comorbidities is necessary when considering older patients for HCT...
- Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantationClaudio G Brunstein
University of Minnesota Blood and Marrow Transplant Program, Minneapolis, Minnesota, USA
Biol Blood Marrow Transplant 15:214-22. 2009..Based on our data, we conclude that a nonmyeloablative conditioning regimen followed by UCB transplantation is an effective treatment for patients with advanced lymphoid malignancies who lack a suitable sibling donor...
- Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantationP Jacobson
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
Bone Marrow Transplant 44:113-20. 2009..600 microg(*)h/ml in 87-100% of subjects. There appears to be no significant difference in daily MPA exposure when MMF of 3 g/day is divided into two or three equal doses...
- Second hematopoietic stem cell transplantation in myeloid malignanciesLisa M Arfons
Department of Medicine, Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio, USA
Curr Opin Hematol 16:112-23. 2009..Herein, we review and examine the data of second allogeneic stem cell transplant after autologous, allogeneic and umbilical cord blood transplantation...
- Autologous hematopoietic stem cell transplant in first remission in non-Hodgkin's lymphomaMarcie Tomblyn
Division of Hematology Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Comprehensive Cancer Center, Chicago, IL 60611, USA
Expert Rev Anticancer Ther 3:281-94. 2003..Based upon the current literature, hematopoietic stem cell transplant cannot be recommended as first-line therapy in patients with non-Hodgkin's lymphoma outside the setting of a clinical trial...